Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Brain, behavior, and immunity

• Publication date

  2017-11-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.bbi.2017.07.005PMID 28698115PMCID PMC5699207
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytokine profile and maternal depression and anxiety symptoms in mid-pregnancy—the FinnBrain Birth Cohort Study

  2017cited by this paper
• Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice

  2017cited by this paper
• Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation

  2017cited by this paper
• Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.

  2017cited by this paper
• Mapping inflammation onto mood: Inflammatory mediators of anhedonia.

  2016cited by this paper
• Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.

  2016cited by this paper
• The role of dopamine in modulation of Th-17 immune response in multiple sclerosis.

  2016cited by this paper
• The Role of Dopamine in Inflammation-Associated Depression: Mechanisms and Therapeutic Implications.

  2016cited by this paper
• RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response

  2015cited by this paper
• Inflammation and clinical response to treatment in depression: A meta-analysis.

  2015cited by this paper
• The role of inflammation in depression: from evolutionary imperative to modern treatment target

  2015cited by this paper
• Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.

  2015cited by this paper
• The role of IL-17 in CNS diseases

  2015cited by this paper
• Thyroid Autoimmune Antibodies and Major Depressive Disorder in Women.

  2015cited by this paper
• ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.

  2015cited by this paper
• Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression

  2015cited by this paper
• Lipopolysaccharide Reduces Incentive Motivation While Boosting Preference for High Reward in Mice

  2014cited by this paper
• An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.

  2014cited by this paper
• Citalopram suppresses thymocyte cytokine production.

  2013cited by this paper
• A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

  2013cited by this paper
• Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease

  2013cited by this paper
• Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder

  2013cited by this paper
• IL-17 cytokines in immunity and inflammation

  2013cited by this paper
• Inflammatory T helper 17 cells promote depression-like behavior in mice.

  2013cited by this paper
• Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance

  2012cited by this paper
• The role of interleukin (IL)‐17 in anxiety and depression of patients with rheumatoid arthritis

  2012cited by this paper
• Induction of Endothelial Nitric Oxide Synthase Expression by IL-17 in Human Vascular Endothelial Cells: Implications for Vascular Remodeling in Transplant Vasculopathy

  2012cited by this paper
• Biomarkers and the Future of Treatment for Depression

  2012cited by this paper
• Impact of antipsychotics on cytokine production in-vitro.

  2011cited by this paper
• Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans

  2011cited by this paper
• Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells.

  2011cited by this paper
• Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis

  2011cited by this paper
• Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

  2011cited by this paper
• How to factor-analyze your data right: do’s, don’ts, and how-to’s.

  2010cited by this paper
• Cellular mechanisms of IL‐17‐induced blood‐brain barrier disruption

  2010cited by this paper
• Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion.

  2009cited by this paper
• From inflammation to sickness and depression: when the immune system subjugates the brain

  2008cited by this paper
• TH17 cells in development: an updated view of their molecular identity and genetic programming

  2008cited by this paper
• Production and functions of IL-17 in microglia.

  2008cited by this paper
• Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation

  2007cited by this paper
• An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.

  2006cited by this paper
• Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

  2006cited by this paper
• Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

  2006cited by this paper
• A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice.

  2006cited by this paper
• Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

  2006cited by this paper
• Self-Rated Global Measure of the Frequency, Intensity, and Burden of Side Effects

  2006cited by this paper
• Medication augmentation after the failure of SSRIs for depression.

  2006cited by this paper
• Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

  2006cited by this paper
• 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

  2005cited by this paper
• A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

  2005cited by this paper
• Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

  2005cited by this paper
• The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation

  2004cited by this paper
• The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

  2003cited by this paper
• Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association.

  2000cited by this paper
• Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor.

  1995cited by this paper
• Bupropion: a review of its mechanism of antidepressant activity.

  1995cited by this paper
• Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor.

  1995cited by this paper

• Interleukin-6 Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Major Depressive Disorder in a Tertiary Care Center

  2026cites this paper
• Immune System Alterations in Depression across Baseline and Flu Vaccine Challenge

  2025cites this paper
• Lessons from clinical trials of immunomodulatory drugs in psychiatric disorders.

  2025cites this paper
• Modulation of neuroimmune cytokine networks by antidepressants: implications in mood regulation

  2025cites this paper
• Comparative Analysis of HPA-Axis Dysregulation and Dynamic Molecular Mechanisms in Acute Versus Chronic Social Defeat Stress

  2025cites this paper
• Monoamine signaling and neuroinflammation: mechanistic connections and implications for neuropsychiatric disorders

  2025cites this paper
• IL-17 enhanced the susceptibility to fluoxetine resistance in depression via the JAK1-STAT6 signaling pathway.

  2025cites this paper
• Dopamine-driven increase in IL-1β in myeloid cells is mediated by differential dopamine receptor expression and exacerbated by HIV

  2025cites this paper
• Genome-wide Mendelian randomization mapping the influence of plasma proteome on major depressive disorder.

  2025cites this paper
• Unbalanced CD4+IL-10+ and more activated and exhausted CD8+ lymphocytes characterized patients with a major depressive episode.

  2025cites this paper
• Unveiling the pathophysiology of restless legs syndrome through transcriptome analysis

  2024influential citation
• Efficacy of a synbiotic in the management of adults with Attention-Deficit and Hyperactivity Disorder and/or Borderline Personality Disorder, and high levels of irritability: Results from a multicenter, randomized, placebo-controlled, "basket" trial.

  2024cites this paper
• Immunotherapy for depression: Recent insights and future targets.

  2024cites this paper
• Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories

  2023cites this paper
• Th17 Cells, Glucocorticoid Resistance, and Depression

  2023cites this paper
• Microbiota Alters and Its Correlation with Molecular Regulation Underlying Depression in PCOS Patients

  2023cites this paper
• Clues from planarians about interleukin-17A and stress that result from light avoidance: IL-17A antagonists reduce defensive responding in flatworms.

  2023cites this paper
• Inflammation in the pathogenesis of depression: a disorder of neuroimmune origin

  2023influential citation
• Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report

  2023cites this paper
• Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics.

  2023cites this paper
• Treatment-Resistant Depression with Anhedonia: Integrating Clinical and Preclinical Approaches to Investigate Distinct Phenotypes.

  2022cites this paper
• Dopamine, Immunity, and Disease

  2022cites this paper
• Targeting IL-17A signaling in suicidality, promise or the long arm of coincidence? Evidence in psychiatric populations revisited

  2022cites this paper
• Th17-cells in depression: Implication in multiple sclerosis

  2022cites this paper
• MicroRNA–Messenger RNA Regulatory Network Mediates Disrupted TH17 Cell Differentiation in Depression

  2022cites this paper
• Inflammatory Biomarker and Response to Antidepressant in Major Depressive Disorder: a Systematic Review and Meta-Analysis.

  2022cites this paper
• Targeting the Adaptive Immune System in Depression: Focus on T Helper 17 Cells

  2022cites this paper
• LOWER ANTIDEPRESSANT RESPONSE TO FLUOXETINE IS ASSOCIATED WITH ANXIETY-LIKE BEHAVIOR, HIPPOCAMPAL OXIDATIVE IMBALANCE, AND INCREASE ON PERIPHERAL IL-17 AND IFN-γ LEVELS.

  2022cites this paper
• Психиатрические аспекты спондилоартритов

  2021cites this paper
• Personalized Medicine Using Neuroimmunological Biomarkers in Depressive Disorders

  2021cites this paper
• An individualized treatment rule to optimize probability of remission by continuation, switching, or combining antidepressant medications after failing a first-line antidepressant in a two-stage randomized trial

  2021cites this paper
• Expansion of CD4 T Lymphocytes Expressing Interleukin 17 and Tumor Necrosis Factor in Patients with Major Depressive Disorder

  2021cites this paper
• PAID study design on the role of PKC activation in immune/inflammation-related depression: a randomised placebo-controlled trial protocol

  2021cites this paper
• Development and Internal Validation of a Novel Model to Identify Inflammatory Biomarkers of a Response to Escitalopram in Patients With Major Depressive Disorder

  2021cites this paper
• Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3

  2021cites this paper
• Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system

  2021cites this paper
• Role of the T-Cell Network in Psychiatric Disorders

  2021cites this paper
• Non-mental diseases associated with ADHD across the lifespan: Fidgety Philipp and Pippi Longstocking at risk of multimorbidity?

  2021cites this paper
• New Insights into Depressive Disorder with Respect to Low-Grade Inflammation and Fish Oil Intake.

  2021cites this paper
• The Bidirectional Relationship of Depression and Inflammation: Double Trouble.

  2020influential citation
• Infiltrated regulatory T cells and Th2 cells in the brain contribute to attenuation of sepsis-associated encephalopathy and alleviation of mental impairments in mice with polymicrobial sepsis.

  2020cites this paper
• Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD.

  2020cites this paper
• Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse.

  2020cites this paper
• The cytokine network in the pathogenesis of major depressive disorder. Close to translation?

  2020cites this paper
• Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder.

  2020cites this paper
• Unipolar depression

  2020cites this paper
• That Gut Feeling: The Role of Inflammatory Cytokines in Depression Among Patients with Inflammatory Bowel Disease

  2020cites this paper
• Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study

  2020cites this paper
• Commentary on Treating Impulsivity with Probiotics in Adults (PROBIA): Study Protocol of a Multicenter, Double-blind, Randomized, Placebo-Controlled Trial

  2020cites this paper
• Review of suicide and depression in psoriasis and management of suicide warnings in patients treated with psoriasis drugs

  2019cites this paper
• Biomarker-Based Treatment Selection: A Precision Medicine Approach for Depression

  2019cites this paper
• Cytokine Research in Depression: Principles, Challenges, and Open Questions

  2019cites this paper
• Pharmacogenomics and Biomarkers of Depression.

  2019cites this paper
• Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD).

  2019cites this paper
• Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial

  2019cites this paper
• Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD

  2019cites this paper
• The cytokine IL‐17A as a marker of treatment resistance in major depressive disorder?

  2019cites this paper
• Dysfunctional adaptive immune response in adolescents and young adults with suicide behavior.

  2019cites this paper
• Dopaminergic impact of cART and anti-depressants on HIV Neuropathogenesis in older adults.

  2019cites this paper
• Anti-Inflammatory Treatments for Major Depressive Disorder: What's on the Horizon?

  2019cites this paper
• An immune gate of depression — Early neuroimmune development in the formation of the underlying depressive disorder

  2019cites this paper
• [Serotonergic system as a therapeutic target in multiple sclerosis].

  2019cites this paper
• Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation

  2018cites this paper
• Association of T and non-T cell cytokines with anhedonia: Role of gender differences.

  2018cites this paper
• Distinct characteristics of hippocampal pathogenic TH17 cells in a mouse model of depression.

  2018cites this paper
• Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.

  2018cites this paper
• Adiponectin Moderates Antidepressant Treatment Outcome in the Combining Medications to Enhance Depression Outcomes Randomized Clinical Trial.

  2018cites this paper
• Elevated Levels of Serum IL-17A in Community-Dwelling Women with Higher Depressive Symptoms

  2018cites this paper
• Inflammatory Markers in Anorexia Nervosa: An Exploratory Study

  2018cites this paper
• Therapeutic potential of JAK/STAT pathway modulation in mood disorders

  2018cites this paper
• The potential of predictive analytics to provide clinical decision support in depression treatment planning

  2018cites this paper
• Involvement of Innate and Adaptive Immune Systems Alterations in the Pathophysiology and Treatment of Depression

  2018cites this paper
• Accurately identifying patients who are excellent candidates or unsuitable for a medication: a novel approach

  2017cites this paper
• Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination

  2017cites this paper